This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
M

ASCO® 2024 Insights: "Impact of ctDNA Surveillance on Clinical Care for Patients With Stage I-III BC"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Marla Lipsyc-Sharf
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Marla Lipsyc-Sharf
217 views
July 24, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

02:58
Lilly Medical Affairs

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy

2024 ASCO® Annual Meeting Insights Hub: Breast Videos

24:36
2024 ASCO® Annual Meeting Insights Hub

ASCO 2024 Highlights: Insights From Key Abstracts on mBC

Feat. S. Aithal
05:06
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Genomic Alterations in HR+/HER2- Metastat…

Feat. M. Bhave
15:31
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Young-PEARL Study - Palbociclib + Exemest…

Feat. Y. Park
View All

Related Content

AUTOPLAY
25:08
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

Feat. S. Tolaney, H. Rugo
05:43
Total Health

Neoadjuvant Chemo for HR+ BC: Year in Review

Feat. C. Ma
33:44
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Expert Recap: "Metastatic Breast Cancer Deep Dive &a…

Feat. S. Tolaney, H. Rugo
06:10
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Summary: "Is There a Role for Combining ADCs W…

Feat. S. Tolaney
13:47
Stanford Medicine

HR+ Advanced/Metastatic BC Treatment Options: Refining Endocrine Sen…

Feat. M. Dolezal
17:35
Insights from 2023 SABCS

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…

Feat. P. Tarantino
09:54
Insights from 2023 ESMO Annual Meeting

Adjuvant Abemaciclib + Endocrine Therapy for HR+, HER2- High-Risk eB…

Feat. J. Huober
05:35
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Insights: "IMpassion132 Trial - Is There a Rol…

Feat. S. Tolaney
35:14
OncoAlert

Advanced TNBC Updates

Feat. H. Rugo
08:41
Insights from 2023 SABCS

SABCS 2023 Insights: "Analysis of ctDNA for the Detection of MR…

Feat. W. Janni
02:35
Integrity CE

SABCS 2023 Summary: "monarchE & NATALEE Trials - Adjuvant T…

Feat. A. Bardia
03:24
ecancer

SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…

Feat. V. Kaklamani
24:05
Robert Wesolowski

Clinical Implications of the EMERALD Data on Treatment Outcomes in H…

08:07
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "SACI-IO HR+ Trial - Sacituzumab Govitecan…

Feat. A. Garrido-Castro
10:54
Yale Cancer Center

De-Escalation of Adjuvant Therapy in Early Stage HER2+ Breast Cancers

Feat. L. Pusztai
26:30
Insights from 2023 SABCS

SABCS 2023 Summary: "HER2+ BC Highlights From KATHERINE & H…

Feat. S. Tolaney, H. Rugo
04:07
ecancer

ASCO® 2024 Insights: "I-SPY2.2 Trial - Pathologic Response to N…

Feat. J. Meisel
17:57
UChicago Medicine

Neoadjuvant & Adjuvant Therapy for High-Risk, Early Stage TNBC

Feat. R. Nanda
14:11
Total Health

Immune Checkpoint Inhibitors and Neoadjuvant Chemo for HR+ BC: Year …

Feat. C. Ma
15:13
Insights from 2023 SABCS

SABCS 2023 Insights: "5-Year Outcomes of the IDEA Trial - ET Wi…

Feat. R. Jagsi